

**January 4, 2008**  
**Announcement no. 02, 2008**

### **Financial calendar 2008**

---

March 11, 2008: Annual report from 01.01.2007 to 31.12.2007

March 28, 2008: Shareholders meeting

May 28, 2008: Interim report – 3 months

August 28, 2008: Interim report – 6 months

November 26, 2008: Interim report – 9 months

### **Further information:**

Christina Tønnesen, Investor Relations  
Tel. no. (+45) 45 29 00 00, e-mail [investor@bioporto.com](mailto:investor@bioporto.com)

### *About BioPorto:*

*BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company's developments include a test (NGAL) to diagnose and monitor acute kidney damage.*

*BioPorto's strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases.*

*BioPorto was founded in 2000 and has about 25 employees. The Company's B shares are listed on OMX Nordic Exchange Copenhagen (symbol: BIOP B). BioPorto is owned by a group of shareholders, none of whom owns more than 5%. [www.bioporto.com](http://www.bioporto.com)*